Disclosure of oral pre-exposure prophylaxis use for HIV prevention among women enrolled in a contraceptive study: qualitative findings from Durban, South Africa.

IF 2.3 Q2 OBSTETRICS & GYNECOLOGY Frontiers in global women's health Pub Date : 2025-01-07 eCollection Date: 2024-01-01 DOI:10.3389/fgwh.2024.1505643
Ivana Beesham, Mags Beksinska, Cecilia Milford, Leila E Mansoor
{"title":"Disclosure of oral pre-exposure prophylaxis use for HIV prevention among women enrolled in a contraceptive study: qualitative findings from Durban, South Africa.","authors":"Ivana Beesham, Mags Beksinska, Cecilia Milford, Leila E Mansoor","doi":"10.3389/fgwh.2024.1505643","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Disclosure of oral pre-exposure prophylaxis (PrEP) use for HIV prevention may improve adherence to PrEP; however, disclosure can be challenging and may result in stigma. Here, we describe disclosure of PrEP use among young women enrolled in a contraceptive study.</p><p><strong>Methods: </strong>In this qualitative study, we conducted semi-structured, in-depth, face-to-face interviews with 13 women aged 18-25 years who initiated oral PrEP for HIV prevention during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial. Interviews were conducted in 2021 with women from Durban, South Africa. In this analysis, we explore women's experiences of PrEP disclosure including whether they disclosed PrEP use, who they disclosed to and the reaction to disclosure, and the impact of disclosure on PrEP use. Interviews were conducted in English, audio-recorded and transcribed. Data were analysed thematically.</p><p><strong>Results: </strong>All women disclosed oral PrEP use to at least one individual, with some women disclosing to multiple individuals including family, friends, partners and community members. Few women did not disclose oral PrEP use to their partner due to anticipating a negative reaction from the partner, feeling that the partner would assume the woman has HIV and is taking antiretroviral therapy and fear that the partner would associate PrEP use with the woman having other partners. Reactions to oral PrEP disclosure were generally supportive or neutral, however, few women reported negative reactions that included distrust in the efficacy of PrEP to prevent HIV, discouraging the woman from using oral PrEP because of the assumption that PrEP is HIV treatment, and concern about the woman having oral PrEP side effects. Negative reactions to disclosure generally did not impact on oral PrEP use. Supportive disclosures sometimes resulted in reminders for oral PrEP dosing.</p><p><strong>Conclusion: </strong>Our findings indicate that women are willing to disclose their PrEP use to at least one other person when supported. These study findings may contribute to future PrEP counselling guidelines and strategies.</p>","PeriodicalId":73087,"journal":{"name":"Frontiers in global women's health","volume":"5 ","pages":"1505643"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11747551/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in global women's health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fgwh.2024.1505643","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Disclosure of oral pre-exposure prophylaxis (PrEP) use for HIV prevention may improve adherence to PrEP; however, disclosure can be challenging and may result in stigma. Here, we describe disclosure of PrEP use among young women enrolled in a contraceptive study.

Methods: In this qualitative study, we conducted semi-structured, in-depth, face-to-face interviews with 13 women aged 18-25 years who initiated oral PrEP for HIV prevention during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial. Interviews were conducted in 2021 with women from Durban, South Africa. In this analysis, we explore women's experiences of PrEP disclosure including whether they disclosed PrEP use, who they disclosed to and the reaction to disclosure, and the impact of disclosure on PrEP use. Interviews were conducted in English, audio-recorded and transcribed. Data were analysed thematically.

Results: All women disclosed oral PrEP use to at least one individual, with some women disclosing to multiple individuals including family, friends, partners and community members. Few women did not disclose oral PrEP use to their partner due to anticipating a negative reaction from the partner, feeling that the partner would assume the woman has HIV and is taking antiretroviral therapy and fear that the partner would associate PrEP use with the woman having other partners. Reactions to oral PrEP disclosure were generally supportive or neutral, however, few women reported negative reactions that included distrust in the efficacy of PrEP to prevent HIV, discouraging the woman from using oral PrEP because of the assumption that PrEP is HIV treatment, and concern about the woman having oral PrEP side effects. Negative reactions to disclosure generally did not impact on oral PrEP use. Supportive disclosures sometimes resulted in reminders for oral PrEP dosing.

Conclusion: Our findings indicate that women are willing to disclose their PrEP use to at least one other person when supported. These study findings may contribute to future PrEP counselling guidelines and strategies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在参加避孕研究的妇女中披露用于艾滋病毒预防的口服暴露前预防使用:来自南非德班的定性研究结果。
背景:披露口服暴露前预防(PrEP)用于艾滋病毒预防可能会提高PrEP的依从性;然而,披露可能具有挑战性,并可能导致耻辱。在这里,我们描述了在参加避孕研究的年轻女性中PrEP使用的披露情况。方法:在这项定性研究中,我们对13名18-25岁的妇女进行了半结构化、深入的面对面访谈,这些妇女在避孕选择和艾滋病毒结局的证据(ECHO)试验期间开始口服PrEP预防艾滋病毒。2021年,对来自南非德班的女性进行了采访。在本分析中,我们探讨了妇女披露PrEP的经历,包括她们是否披露了PrEP的使用情况,她们向谁披露了信息以及对披露的反应,以及披露对PrEP使用的影响。采访以英文进行,录音和文字记录。数据按主题进行分析。结果:所有女性至少向一人披露口服PrEP使用情况,部分女性向包括家人、朋友、伴侣和社区成员在内的多人披露。很少有妇女不向其伴侣透露口服PrEP的使用情况,因为她们预计伴侣会有负面反应,认为伴侣会认为该妇女感染了艾滋病毒并正在接受抗逆转录病毒治疗,并担心伴侣会将使用PrEP与该妇女有其他伴侣联系起来。对口服PrEP披露的反应通常是支持或中立的,然而,很少有妇女报告负面反应,包括不信任PrEP预防艾滋病毒的功效,因为PrEP是艾滋病毒治疗的假设而不鼓励妇女使用口服PrEP,以及担心口服PrEP的副作用。对信息披露的负面反应一般不会影响口服PrEP的使用。支持性披露有时会导致提醒口服PrEP剂量。结论:我们的研究结果表明,在得到支持的情况下,女性愿意向至少一个人透露她们使用PrEP的情况。这些研究结果可能有助于未来的PrEP咨询指南和策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.70
自引率
0.00%
发文量
0
审稿时长
13 weeks
期刊最新文献
Unexplored avenues: a narrative review of cognition and mood in postmenopausal African women with female genital circumcision/mutilation/cutting. Changes in health related quality of life in mothers with inflammatory joint disease from year 2000 to 2020 - a comparative cross-sectional study. Predictors of client satisfaction with family planning services in Ethiopia: a systematic review and meta-analysis. Disclosure of oral pre-exposure prophylaxis use for HIV prevention among women enrolled in a contraceptive study: qualitative findings from Durban, South Africa. A study on sexual violence among women in Northern Ethiopia's 2022 conflict: mixed methods.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1